The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

April 20, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270AXS-02 in a Phase 3 Clinical Trial for Knee OA
AXS-02 (disodium zoledronate tetrahydrate) is an osteoclast inhibitor currently in a Phase 3 clinical trial as a targeted, non-opioid oral therapy for managing chronic pain.1 Known as COAST-1 (Clinical Knee Osteoarthritis Symptom Treatment 1), the study is evaluating the safety and efficacy of disodium zoledronate tetrahydrate on pain in patients with knee osteoarthritis (OA).

You Might Also Like
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial
Also By This Author
  • 2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA

Disodium zoledronate tetrahydrate has a high affinity for bone mineral and reduces osteoclast activity by inhibiting the farnesyl pyrophosphate synthase (FPPS) enzyme. The therapy is being developed to treat complex regional pain syndrome (CRPS) and knee OA pain associated with bone marrow lesions. It is also being investigated to treat chronic lower back pain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Ixekizumab Receives FDA Approval for Plaque Psoriasis
Ixekizumab (Taltz) binds to interleukin (IL)-17A, suppressing inflammation. Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. It has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.2 The treatment is available as an auto-injector and as a prefilled syringe.

Ixekizumab is administered subcutaneously at a dose of 160 mg or two 80 mg injections at Week 0, followed by 80 mg injections at Weeks 2, 4, 6, 8, 10 and 12. Patients then receive 80 mg Ixekizumab every four weeks.3 In clinical trials, the most common adverse reactions were injection site reactions, upper respiratory tract infections, nausea and tinea infections.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Belimumab May Reduce Steroid Use in SLE
In pooled data from two large randomized controlled clinical trials, belimumab, the B-lymphocyte stimulator (BLyS)-specific inhibitor, had a moderate association with a greater likelihood of steroid dose reduction over 52 weeks in patients with systemic lupus erythematosus (SLE).4

Compared with placebo-treated patients, dose reduction occurred in 39% of belimumab-treated patients compared to 31% of placebo-treated recipients. Dose augmentation occurred in 18% vs. 31% of belimumab- and placebo-treated patients, respectively. Steroid dose increase occurred in 23% of belimumab-treated patients vs. 35% of placebo-treated patients. The steroid doses decreased in more belimumab-treated patients (37%) than placebo-treated patients (30%).


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Axsome Therapeutics Inc. News release: Axsome Therapeutics initiates phase 3 study of AXS-02 for knee osteoarthritis associated with bone marrow lesions. 2016 Mar 28.
  2. U.S. Food and Drug Administration. News release: FDA approves new psoriasis drug Taltz. 2016 Mar 22.
  3. U.S. Food and Drug Administration. Taltz label information. 2016 Mar 22.
  4. Swift D. Benlysta found steroid-sparing in lupus: Modest effects in prednisone dose reduction seen in post-hoc analyses. MedPage Today. 2016 Mar 26.

Pages: 1 2 | Multi-Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: belimumab, disodium zoledronate tetrahydrate, FDA, Food and Drug Administration, ixekizumab, Knee Osteoarthritis (OA), Pain, plaque psoriasis, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial
  • U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)